Previous Close | 55.12 |
Open | 54.27 |
Bid | 52.86 x 800 |
Ask | 53.06 x 900 |
Day's Range | 52.78 - 54.75 |
52 Week Range | 26.10 - 129.09 |
Volume | |
Avg. Volume | 1,336,079 |
Market Cap | 5.278B |
Beta (5Y Monthly) | 1.33 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -5.89 |
Earnings Date | Nov 02, 2022 - Nov 07, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 84.91 |
Subscribe to Yahoo Finance Plus to view Fair Value for NTRA
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced full enrollment for the RenaCARE (Renasight Clinical Application, Review and Evaluation) study, a real world, prospective, multi-center clinical study to assess the clinical utility of Natera's Renasight™ genetic testing panel, which analyzes more than 380 genes related to kidney disease. Enrollment in the study was completed early as a result of statistically meaningful interim data analysis. The study includ
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced earlier today at the Canaccord Genuity 42nd Annual Growth Conference in Boston that the company has proactively filed a pre-submission to the FDA for its Panorama® non-invasive prenatal test (NIPT) as part of the Q-Sub process. The company filed its pre-submission in June 2022 for fetal chromosomal aneuploidies and for 22q11.2 deletion syndrome.
Natera (NTRA) delivered earnings and revenue surprises of -2.04% and 2.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?